<p>Cardiol Therapeutics Inc.（多倫多證券交易所代碼：CRDL - 獲取免費報告）在週一的午盤交易中股價下跌了 17.2%。該公司的股價最低曾達到 C$1.24，最後交易價為 C$1.25。午盤交易中大約有 480,129 股成交，較平均每日成交量 108,711 股增加了 342%。該股票此前收盤價為 C$1.51。</p>
<p>獲取 <strong>Cardiol Therapeutics</strong> 的提醒：</p>
<h2>Cardiol Therapeutics 價格表現</h2>
<p>該公司的市值為 1.29 億加元，市盈率為-3.15，貝塔值為 1.31。公司的債務與股本比率為 1.59，流動比率為 2.49，速動比率為 6.84。該公司的 50 日移動平均線為 C$1.50，200 日移動平均線為 C$1.65。</p>
<p>Cardiol Therapeutics（多倫多證券交易所代碼：CRDL - 獲取免費報告）最近在 11 月 13 日（星期四）發佈了季度財報。該公司報告本季度每股收益（EPS）為 C($0.12)。分析師預測 Cardiol Therapeutics Inc.在當前財政年度將發佈-0.49 的每股收益。</p>
<h2>關於 Cardiol Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Cardiol Therapeutics Inc.（納斯達克代碼：CRDL，TSX 代碼：CRDL）是一家臨牀階段的生命科學公司，專注於心髒病的抗炎和抗纖維化療法的研究與臨牀開發。該公司的主要藥物候選者 CardiolRxTM（大麻二酚）口服溶液，經過藥品製造，並正在進行臨牀開發，用於治療心臟病。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Cardiol Therapeutics 更好</li>
<li>如何投資小盤股</li>
<li>與三隻頂級零售 ETF 一起購物</li>
<li>異常成交量的股票：如何實時找到異常成交量股票</li>
<li>如果 D-Wave 風險太大，可以考慮這三隻量子 ETF 進行多元化投資</li>
<li>如何選擇頂級評級股票</li>
<li>NVIDIA 的 13F 揭示了兩個第三季度贏家——以及一個痛苦的失誤</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Cardiol Therapeutics 嗎？</h2>
<p>在考慮 Cardiol Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Cardiol Therapeutics 並不在名單上。</p>
<p>雖然 Cardiol Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CRDL

<p>Cardiol Therapeutics（多倫多證券交易所代碼：CRDL）在週一的午盤交易中股價下跌了 17.2%，最低交易價格為 1.24 加元。該股票的交易量顯著增加，共有 480,129 股易手。該公司的市值為 1.29 億加元，報告的季度每股虧損為 0.12 加元。Cardiol Therapeutics 專注於開發針對心臟病的抗炎和抗纖維化療法。儘管分析師給予其 “持有” 評級，但一些人認為在其他地方有更好的投資機會</p>

<p>Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) shares were down 17.2% during mid-day trading on Monday . The company traded as low as C$1.24 and last traded at C$1.25. Approximately 480,129 shares changed hands during mid-day trading, an increase of 342% from the average daily volume of 108,711 shares. The stock had previously closed at C$1.51.</p>
<div class="lb-trans"><p>Cardiol Therapeutics Inc.（多倫多證券交易所代碼：CRDL - 獲取免費報告）在週一的午盤交易中股價下跌了 17.2%。該公司的股價最低曾達到 C$1.24，最後交易價為 C$1.25。午盤交易中大約有 480,129 股成交，較平均每日成交量 108,711 股增加了 342%。該股票此前收盤價為 C$1.51。</p>
</div><p>Get <strong>Cardiol Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Cardiol Therapeutics</strong> 的提醒：</p>
</div><h2>Cardiol Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Cardiol Therapeutics 價格表現</h2>
</div><p>The company has a market capitalization of C$129.00 million, a P/E ratio of -3.15 and a beta of 1.31. The company has a debt-to-equity ratio of 1.59, a current ratio of 2.49 and a quick ratio of 6.84. The firm's 50-day moving average is C$1.50 and its 200-day moving average is C$1.65.</p>
<div class="lb-trans"><p>該公司的市值為 1.29 億加元，市盈率為-3.15，貝塔值為 1.31。公司的債務與股本比率為 1.59，流動比率為 2.49，速動比率為 6.84。該公司的 50 日移動平均線為 C$1.50，200 日移動平均線為 C$1.65。</p>
</div><p>Cardiol Therapeutics (TSE:CRDL - Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The company reported C($0.12) earnings per share (EPS) for the quarter. Analysts predict that Cardiol Therapeutics Inc. will post -0.49 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Cardiol Therapeutics（多倫多證券交易所代碼：CRDL - 獲取免費報告）最近在 11 月 13 日（星期四）發佈了季度財報。該公司報告本季度每股收益（EPS）為 C($0.12)。分析師預測 Cardiol Therapeutics Inc.在當前財政年度將發佈-0.49 的每股收益。</p>
</div><h2>About Cardiol Therapeutics</h2>
<div class="lb-trans"><h2>關於 Cardiol Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Cardiol Therapeutics Inc NASDAQ: CRDLTSX: CRDL is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.</p>
<div class="lb-trans"><p>Cardiol Therapeutics Inc.（納斯達克代碼：CRDL，TSX 代碼：CRDL）是一家臨牀階段的生命科學公司，專注於心髒病的抗炎和抗纖維化療法的研究與臨牀開發。該公司的主要藥物候選者 CardiolRxTM（大麻二酚）口服溶液，經過藥品製造，並正在進行臨牀開發，用於治療心臟病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Cardiol Therapeutics</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Go on a Shopping Spree With 3 Top Retail ETFs</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>If D-Wave Is Too Risky, Consider These 3 Quantum ETFs for Diversification</li>
<li>How to Choose Top Rated Stocks</li>
<li>NVIDIA’s 13F Reveals 2 Q3 Winners—And 1 Painful Miss</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Cardiol Therapeutics 更好</li>
<li>如何投資小盤股</li>
<li>與三隻頂級零售 ETF 一起購物</li>
<li>異常成交量的股票：如何實時找到異常成交量股票</li>
<li>如果 D-Wave 風險太大，可以考慮這三隻量子 ETF 進行多元化投資</li>
<li>如何選擇頂級評級股票</li>
<li>NVIDIA 的 13F 揭示了兩個第三季度贏家——以及一個痛苦的失誤</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cardiol Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Cardiol Therapeutics 嗎？</h2>
</div><p>Before you consider Cardiol Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Cardiol Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Cardiol Therapeutics 並不在名單上。</p>
</div><p>While Cardiol Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cardiol Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Cardiol Therapeutics (TSE:CRDL) 股價下跌 17.2% - 以下是發生的情況